Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 11/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25308496 | 0.81 | EGLN1 (0.46) | PTGS1PTGS2EGLN1CYP1A2CYP3A4 | |
| SCHEMBL8607604 | 0.80 | PTGS1 (0.50) | PTGS1PTGS2EGLN1CYP1A2CYP3A4 | |
| SCHEMBL3498034 | 0.78 | PTGS1 (0.58) | PTGS1PTGS2EGLN1CYP1A2CYP3A4 | |
| SCHEMBL8607242 | 0.78 | P4HTM (0.50) | PTGS1PTGS2EGLN1 | |
| SCHEMBL8608756 | 0.77 | PTGS1 (0.53) | PTGS1PTGS2EGLN1CYP1A2CYP3A4 | |
| SCHEMBL8608817 | 0.75 | TBXAS1 (0.49) | PTGS1PTGS2EGLN1CYP1A2MAPT | |
| SCHEMBL8346854 | 0.75 | PTGS1 (0.35) | PTGS1PTGS2CYP1A2CYP3A4MAPT | |
| SCHEMBL8609927 | 0.75 | PTGS1 (0.48) | PTGS1PTGS2EGLN1CYP1A2CYP3A4 | |
| SCHEMBL8609437 | 0.73 | PTGS1 (0.46) | PTGS1PTGS2EGLN1CYP1A2CYP3A4 | |
| SCHEMBL28626437 | 0.73 | PTGS1 (0.59) | PTGS1PTGS2EGLN1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5633237-A | Imidazo[1,2-a]pyridinylalkyl phosphonic acid compounds for treatment of neurotoxic injury | G.D. SEARLE & CO. (US) | 1997-05-27 | — | — | US | claimed |
| US-5360796-A | Treatment of hypoxia, anoxia or ischemia | G. D. SEARLE & CO. (US) | 1994-11-01 | — | — | US | claimed |
| EP-0436831-A2 | Imidazo[1,2-a]pyridinylalkyl compounds for treatment of neurotoxic injury | G.D. Searle & Co. (US) | 1991-07-17 | — | — | EP | claimed |
| WO-1991008211-A1 | IMIDAZO[1,2-a]PYRIDINYLALKYL COMPOUNDS FOR TREATMENT OF NEUROTOXIC INJURY | G.D. SEARLE & CO. (US) | 1991-06-13 | — | — | WO | claimed |
| US-5716964-A | BRAIN DISORDERS; ANTIISCHEMIC AGENTS | G.D. SEARLE & CO. (US) | 1998-02-10 | — | — | US | disclosed |
| US-5633237-A | Imidazo[1,2-a]pyridinylalkyl phosphonic acid compounds for treatment of neurotoxic injury | G.D. SEARLE & CO. (US) | 1997-05-27 | — | — | US | disclosed |
| US-5360796-A | Treatment of hypoxia, anoxia or ischemia | G. D. SEARLE & CO. (US) | 1994-11-01 | — | — | US | disclosed |
| EP-0436831-A2 | Imidazo[1,2-a]pyridinylalkyl compounds for treatment of neurotoxic injury | G.D. Searle & Co. (US) | 1991-07-17 | — | — | EP | disclosed |
| WO-1991008211-A1 | IMIDAZO[1,2-a]PYRIDINYLALKYL COMPOUNDS FOR TREATMENT OF NEUROTOXIC INJURY | G.D. SEARLE & CO. (US) | 1991-06-13 | — | — | WO | disclosed |